Glenmark gets USFDA approval for Clindamycin Phosphate Foam 1%

Glenmark


Chennai, Sep 21 : Pharma major Glenmark Pharmaceuticals Ltd on Tuesday said it has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1 per cent, the generic version of Evoclin Foam, 1 per cent, of Mylan Pharmaceuticals Inc. According to IQVIA sales data for the 12 month period ending July 2021, the Evoclin Foam, 1 per cent, market achieved annual sales of approximately $12.0 million. Glenmark's current portfolio consists of 173 products authorized for distribution in the US marketplace and 47 ANDA's (Abbreviated New Drug Application) pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, the company said. /IANS




Related

K'taka releases new guidelines for international passengers
Bengaluru, Nov 29 : The Karnataka government announced fresh guidelines for international arrivals on Monday. As per the circular released by th

Daily Covid cases in India fall below 10,000 3rd day in a row
New Delhi, Nov 29 : India on Monday reported 8,309 fresh Covid cases in the last 24 hours, below the 10,000-mark for three days in a row. In the same

3 foreign nationals test Covid positive in Mathura
Mathura (Uttar Pradesh), Nov 29 : Even as concerns over the highly transmissible Covid variant Omicron detected abroad soar, three foreign nationals,